DS-7113b phase III study

Phase 3

• Conditions: Moderate to severe cancer pain

• Registration Number: JPRN-jRCT2080222239
• Lead Sponsor: DAIICHISANKYO Co.,Ltd.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-09-30
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Cancer pain patients meeting any of followings
-Patients on opioid analgesics (oral morphine, oral oxycodone, transdermal fentanyl, or tramadol) less than 240 mg in morphine equivalent and judged effective to be treated with strong opioid analgesics
-Patients who have not been on opioid analgesics, whose VAS is 35 mm and over and judged necessary to be treated with strong opioid analgesics
-Patients who prefer to take DS-7113b IR tabletsafter completion of the study treatment of DS7113-A-J301 trial

Exclusion Criteria

Patients with symptom(s)/finding(s) falling under the contraindications or relative contraindications stated in the package insert of oxycodone hydrochloride and morphine hydrochloride, etc.

Study & Design

• Study Type: Interventional
• Study Design: Not specified